A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.

Saved in:
Bibliographic Details
Title: A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
Authors: Zibelman M; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. matthew.zibelman@fccc.edu., MacFarlane AW 4th; Immune Monitoring/Cell Sorting Facility, Institute for Cancer Research, Philadelphia, PA, USA., Costello K; Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, PA, USA., McGowan T; Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, PA, USA., O'Neill J; Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, PA, USA., Kokate R; Office of Clinical Research, Fox Chase Cancer Center, Philadelphia, PA, USA., Borghaei H; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Denlinger CS; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Dotan E; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Geynisman DM; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Jain A; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Martin L; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Obeid E; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Devarajan K; Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA., Ruth K; Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA., Alpaugh RK; Protocol Support Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA., Dulaimi EA; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA., Cukierman E; Cancer Signaling and Microenvironment Program, Marvin and Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, USA., Einarson M; High Throughput Screening Facility, Fox Chase Cancer Center, Philadelphia, PA, USA., Campbell KS; Immune Monitoring/Cell Sorting Facility, Institute for Cancer Research, Philadelphia, PA, USA., Plimack ER; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Source: Nature communications [Nat Commun] 2023 Jul 27; Vol. 14 (1), pp. 4513. Date of Electronic Publication: 2023 Jul 27.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-1723
DOI:10.1038/s41467-023-40028-z